Cholesterol or Inflammation ?

https://www.washingtonpost.com/amphtml/news/wonk/wp/2017/08/27/major-drug-study-opens-up-vast-new-opportunities-in-combating-heart-disease/

"By testing a Novartis drug that only affected inflammation — without budging cholesterol — researchers were able to show for the first time that the approach could reduce cardiovascular risk."

“To me, this is like rolling back the clock on statins all the way back to 1994. The first statin came out and we said, ‘Wow, here’s a new class of drugs that can really impact on heart attack and stroke,' " said Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston who has doggedly pursued the “inflammatory hypothesis” of heart disease for more than two decades. Ridker has served as a paid consultant to Novartis. “This is the first step, but a big one that is very exciting.”